Population pharmacokinetics of rosuvastatin: Implications of renal impairment, race and dyslipidaemia

Current Medical Research and Opinion

Volumn 24, Issue 9, 2008, Pages 2575-2585

  Tzeng, Tsang Bin ^a   Schneck, Dennis W ^a   Birmingham, Bruce K ^a   Mitchell, Patrick D ^a   Zhang, Harry ^a   Martin, Paul D ^a   Kung, Li Pin ^b  

^a ASTRAZENECA   (United Kingdom)

^b MegaMed Pharmaceutical Research Institute   (United States)

Author keywords

Covariates; Dyslipidaemia; Population pharmacokinetics; Race; Renal impairment; Rosuvastatin

Indexed keywords

PLACEBO; ROSUVASTATIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASIAN; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DYSLIPIDEMIA; FIRST PASS EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; KIDNEY FAILURE; KIDNEY FUNCTION TEST; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; POPULATION RESEARCH; RACE DIFFERENCE; REPEATED DRUG DOSE; SINGLE DRUG DOSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTINENTAL POPULATION GROUPS; DYSLIPIDEMIAS; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; TANDEM MASS SPECTROMETRY;

EID: 53349153621     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802312807     Document Type: Article

References (22)

1. Igel M, Sudhop T, von Bergmann K. Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin. J Clin Pharmacol 2002; 42:835-45
2. Scott LJ, Curran MP, Figgitt DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs 2004;4:117-38
3. Hull CK, Penman AD, Smith CK, et al. Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002;772:219-28
4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
5. Boeckmann AJ, Sheiner LB, Beat SL. NONMEM Users' Guide-Part V: Introductory Guide. NONMEM Project Group C255 University of California at San Francisco. Regents of the University of California, 1991.
6. Cooper KJ, Martin PD, Dane AL, et al. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2003;59:51-6
7. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002;42:963-70
8. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther 2003;25:2822-35
9. Martin PD, Warwick MJ, Dane AL, et al. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin Ther 2003;25:2553-63
10. Schneck DW, Birmingham BK, Zalikowski JA, et al. The effect of genifibrozil on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2004;75:455-63
11. Cooper KJ, Martin PD, Dane AL, et al. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin Pharmacol Ther 2003;73:322-9
12. Cooper KJ, Martin PD, Dane AL, et al. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br J Clin Pharmacol 2003;55:94-9
13. Cooper KJ, Martin PD, Dane AL, et al. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002;58:527-31
14. Martin PD, Dane AL, Nwose OM, et al. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J Clin Pharmacol 2002;42: 1116-21
15. Martin PD, Warwick MJ, Dane AL, et al. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin Ther 2003;25:2215-24
16. Martin PD, Dane AL, Schneck DW, et al. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin Ther 2003;25:459-71
17. Sekino H, Onishi T. Phase I study of ZD4522 (rosuvastatin), a new HMG-CoA reductase inhibitor-evaluation of tolerance and pharmacokinetics in healthy adult male volunteers after single and repeated oral administration. J Clin Ther Med 2005; 21:187-203
18. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics; of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol 2002;54:472-7
19. Warwick MJ, Dane AL, Raza A, et al. Single- and multiple-dose pharmacokinetics and safety of the new HMG-CoA reductase inhibitor ZD4522 [abstract]. Atherosclerosis 2000;151:39
20. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005; 78:330-41
21. Simonson SG, Raza A, Martin PD, et al. Rosuvastatin pharmacokinetics in heart transplant recipients administered an anti-rejection regimen including cyclosporine. Clin Pharmacol Ther 2004;76:167-77
22. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol 2007;99:410-14